Large-Scale Skin Cancer Screening Initiative Feasible

Share this content:
Large-Scale Skin Cancer Screening Initiative Feasible
Large-Scale Skin Cancer Screening Initiative Feasible

FRIDAY, Feb. 24, 2017 (HealthDay News) -- Large-scale skin cancer screening, including full-body skin examination (FBSE) is feasible and increases diagnosis of melanoma and thinner invasive melanoma, according to a study published online Feb. 23 in JAMA Oncology.

Laura K. Ferris, M.D., Ph.D., from the University of Pittsburgh, and colleagues describe a skin cancer screening initiative implemented in a large health care system among adults seen during an office visit with a University of Pittsburgh Medical Center-employed primary care physician. The intervention included implementation of a campaign promoting annual skin cancer screening by FBSE.

The researchers found that 15.9 percent of the screen-eligible population of 333,735 adult patients received FBSE. Overall, 50 and 104 melanomas were diagnosed in screened and unscreened patients, respectively. Compared with unscreened patients, screened patients were more likely to be diagnosed with a melanoma (adjusted risk ratio, 2.4; 95 percent confidence interval, 1.7 to 3.4; P < 0.001) and to have a thinner invasive melanoma (median thickness, 0.37 versus 0.65 mm; P < 0.001). Screened and unscreened patients had similar incidence of melanoma lesions 1 mm or thicker (adjusted risk ratio, 0.7; 95 percent confidence interval, 0.2 to 2.2; P = 0.52).

"Large-scale screening for melanoma within a U.S. health care system is feasible and can result in increased detection of thinner melanomas," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »